# Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis

> **NCT01065727** · NA · UNKNOWN · sponsor: **Rennes University Hospital** · enrollment: 250 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **OTHER:** mitoxantrone - immunomodulator
- **OTHER:** natalizumab

## Key facts

- **NCT ID:** NCT01065727
- **Lead sponsor:** Rennes University Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-02
- **Primary completion:** 2016-02
- **Final completion:** 2019-02
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2012-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01065727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01065727, "Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01065727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*